February 22, 2024

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug Administration Enrollment completed in phase 3 TRIDENT trial studying the use of TTFields therapy and concomitant radiation for the treatment… Read More
learn more
January 18, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted… Read More
learn more
January 9, 2024

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

Final data from the TRIDENT trial anticipated in 2026 ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio® (formerly known as Optune®) concurrent with… Read More
learn more
January 8, 2024

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D., Ph.D. appointed as Novocure Chief Medical Officer, effective January 1, 2024 Novocure to present at… Read More
learn more
January 4, 2024

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncologist… Read More
learn more